Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers
暂无分享,去创建一个
A. Schmitt-Hoffmann | B. Roos | E. Weidekamm | J. Maares | M. Heep | Michael Roehrle | Jochen Spickerman | Thomas Brown
[1] C. Beglinger,et al. Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers , 2006, Antimicrobial Agents and Chemotherapy.
[2] O. Cornely,et al. Recent developments in the management of invasive fungal infections in patients with hematological malignancies , 2005, Annals of Hematology.
[3] M. Galteau,et al. Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals , 2003, European Journal of Clinical Pharmacology.
[4] M. Boogaerts,et al. Pharmacokinetics and Safety of a 7-Day Administration of Intravenous Itraconazole followed by a 14-Day Administration of Itraconazole Oral Solution in Patients with Hematologic Malignancy , 2001, Antimicrobial Agents and Chemotherapy.
[5] F. Granier. [Invasive fungal infections. Epidemiology and new therapies]. , 2000, Presse medicale.
[6] M. Ghannoum,et al. New investigational antifungal agents for treating invasive fungal infections , 2000, Expert opinion on investigational drugs.
[7] K. Holmes,et al. Introduction to the 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] T. Davis,et al. Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: a previously unrecognized clinical entity. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] B. Guglielmo,et al. Lipid formulations of amphotericin B: clinical efficacy and toxicities. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] R C Spencer,et al. Fungal Infection: Diagnosis and Management , 1998 .
[11] K. Holmes,et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[13] M. Prenna,et al. Pharmacokinetics of fluconazole in normal volunteers. , 1993, Chemotherapy.
[14] D. Back,et al. Azoles, a48 llylamines and drug metabolism , 1992 .
[15] D. Back,et al. Azoles, allylamines and drug metabolism. , 1992, The British journal of dermatology.
[16] M. Brodie,et al. Effect of rifampicin on haem and bilirubin metabolism in man. , 1987, British journal of clinical pharmacology.
[17] A. Karim. The pharmacokinetics of Norpace. , 1975, Angiology.